Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: Clin Genitourin Cancer. 2021 Mar 19;19(5):405–416. doi: 10.1016/j.clgc.2021.03.011

Fig. 4. [18F]-BF3-Cy3-ACUPA PET/CT imaging of Patient 8.

Fig. 4

Patient 8 was a candidate for RP based on prior biopsy and [68Ga]-PSMA-11 imaging. As part of this study, this patient underwent [18F]-BF3-Cy3-ACUPA injection and PET/CT imaging, followed by RP ~24 hours later. A) [68Ga]-PSMA-11 PET MIP image. B) [18F]-BF3-Cy3-ACUPA PET MIP image. C) [68Ga]-PSMA-11 PET/CT image shows localized PSMA+ disease (arrow) but no nodal or distant disease. D) Similar PET delineations (magenta arrowheads) are observed on the 90-min post-injection [18F]-BF3-Cy3-ACUPA PET/CT image. Without reinjection, the patient underwent RP 24 hours later (after 18F decayed). E) Fluorescence images of excised prostate tissue using a first-generation back-table Cy3 fluorescence imaging device. F) Post-surgical prostate co-registration shows PCa in an MRI apparent diffusion coefficient image, PET image, and fluorescence image; post-surgical fluorescence image shows a positive margin in the posterior urethra/bladder neck (indicated by a dashed magenta border).